YOLFTbeta
68

Shanghai OPM Biosciences Co. Ltd. A

688293 · SHG · Healthcare / Biotechnology

64.90CNY-3.93 (-5.71%)

Price History

Full chart

Market Stats

Previous Close68.83
Open68.57
Day Range63.71 – 69.59
52-Week Range33.97 – 88.54
Volume5.10M
Market Cap11.32B
P/E (TTM)162.47
Forward P/E0.00
EPS0.49
Dividend Yield0.50%
Beta0.66
50-Day Avg62.38
200-Day Avg51.84

About

Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, OPM-Vac platform, OPM-Hybri Platform, VegaCHO media and feeds, as well as customized cell culture media development services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development, cell banking, upstream process development, downstream process development, formulation development, and quality control and product characterization of biologics. The company was founded in 2013 and is headquartered in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Zhihua Xiao
  • Employees102
  • HeadquartersBuilding 28, Shanghai, China, 201321, China
  • Websitehttps://www.opmbiosciences.com

Leadership

  • Dr. Zhihua XiaoChairman & GM · b. 1974
  • Ms. Liangping NiCFO, Accounting Supervisor, Deputy GM & Director · b. 1984
  • Ms. Yun Fen HeDeputy GM & Director · b. 1979
  • Ms. Xiaohan MaSecretary to the Board · b. 1990

Financials

Income Statement

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue124.97M212.68M294.37M243.12M297.24M354.91M
Growth (%)-+70.19%+38.41%-17.41%+22.26%+19.40%
Cost of Revenue67.50M85.32M106.06M100.05M139.62M174.44M
Gross Profit57.48M127.36M188.30M143.07M157.62M180.47M
Gross Margin45.99%59.88%63.97%58.85%53.03%50.85%
Operating Expense47.45M66.72M84.41M109.82M139.66M142.66M
Operating Income10.03M60.64M103.89M33.25M17.96M37.81M
Operating Margin8.02%28.51%35.29%13.67%6.04%10.65%
EBITDA--158.27M101.73M85.56M102.47M
EBITDA Margin--53.77%41.84%28.79%28.87%
Net Income11.68M60.39M105.37M54.04M21.05M41.70M
Net Income Margin9.35%28.40%35.80%22.23%7.08%11.75%
R&D22.56M19.69M33.20M43.06M34.19M48.38M
R&D as % of Total Revenue18.05%9.26%11.28%17.71%11.50%13.63%
Interest Expense2.45M4.79M4.98M3.23M3.12M2.69M
Interest Expense % of Total Revenue1.96%2.25%1.69%1.33%1.05%0.76%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-616.86M747.08M2.35B2.30B2.29B2.25B
Total Liabilities-122.88M184.62M163.07M144.21M190.97M148.29M
Total Equity-493.99M562.45M2.18B2.16B2.10B2.10B
Cash-309.19M310.34M1.51B1.28B891.14M787.45M
Net Debt22.37M------

Cash Flow

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow3.20M114.63M111.62M57.95M69.25M103.39M
Capital Expenditure36.24M99.20M146.96M77.55M120.86M56.07M
Free Cash Flow-33.04M15.42M-35.34M-19.59M-51.61M47.32M
Dividends Paid2.14M1.80M2.08M73.83M51.22M48.83M
FCF to OCF-1031.57%13.45%-31.66%-33.81%-74.54%45.77%
Dividend Paid to FCF-6.48%11.70%-5.88%-376.81%-99.23%103.17%

Earnings

Report DateOct 26, 2022Feb 23, 2023Apr 27, 2023
EPS Estimate---
EPS Actual0.360.270.30
Surprise---
TimingPre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap11.32B
Enterprise Value11.15B
Trailing P/E162.47
Forward P/E0.00
Price / Sales17.94
Price / Book3.85
EPS0.49
Book Value22.10
Revenue (TTM)630.86M
Gross Profit (TTM)281.77M
EBITDA103.20M
Profit Margin20.32%
Operating Margin17.49%
Return on Equity4.77%
Return on Assets1.03%
Shares Outstanding142.19M
Shares Float103.73M
Beta0.66
Dividend Yield0.50%
Dividend Rate0.40
Payout Ratio46.94%

Dividends

20262×
0.20Oct 27, 20260.20Jul 10, 2026
20252×
0.23Sep 15, 20250.20May 23, 2025
20242×
0.22Sep 20, 20240.23Jun 13, 2024
20232×
0.21Oct 11, 20230.60May 12, 2023

Stock Splits

  • May 12, 20231.4:1